These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 33878170)

  • 1. Acquired haemophilia A in a patient with limited cutaneous systemic sclerosis.
    Glas HK; Kwok WY; Ypma PF; Goekoop RJ
    Rheumatology (Oxford); 2021 Oct; 60(10):e360-e361. PubMed ID: 33878170
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased prevalence of anti-thyroid antibodies in patients with limited scleroderma: comments on the article by Danielides et al.
    Park SJ; Shin JI
    Scand J Rheumatol; 2012 May; 41(3):248. PubMed ID: 22548259
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
    Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
    Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
    Mondini M; Vidali M; De Andrea M; Azzimonti B; Airò P; D'Ambrosio R; Riboldi P; Meroni PL; Albano E; Shoenfeld Y; Gariglio M; Landolfo S
    Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Classification criteria of scleroderma].
    Cabane J;
    Presse Med; 2006 Dec; 35(12 Pt 2):1916-22. PubMed ID: 17159717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais.
    Foocharoen C; Watcharenwong P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R
    Int J Rheum Dis; 2017 Oct; 20(10):1572-1581. PubMed ID: 28296274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic sclerosis in Argentina: evaluation of a large cohort from a single centre and comparison with other international series.
    Scolnik M; Lancioni E; Saucedo C; Marin J; Sabelli M; Bedran Z; Soriano ER; Catoggio LJ
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-94-7. PubMed ID: 25198424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute exacerbation of interstitial lung disease with onset of myositis in systemic sclerosis patients: a report of two cases.
    Nakamura K; Ichimura Y; Tamaki Z; Yoshizaki A; Sato S; Asano Y
    Scand J Rheumatol; 2020 May; 49(3):247-248. PubMed ID: 32102590
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I.
    Foocharoen C; Suwannachat P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R;
    Int J Rheum Dis; 2016 Mar; 19(3):312-20. PubMed ID: 25293362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of UBE2L3 polymorphisms with diffuse cutaneous systemic sclerosis in a Japanese population.
    Hasebe N; Kawasaki A; Ito I; Kawamoto M; Hasegawa M; Fujimoto M; Furukawa H; Tohma S; Sumida T; Takehara K; Sato S; Kawaguchi Y; Tsuchiya N
    Ann Rheum Dis; 2012 Jul; 71(7):1259-60. PubMed ID: 22294623
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: Association with extent of skin sclerosis.
    Yanaba K; Hayashi M; Yoshihara Y; Nakagawa H
    J Dermatol; 2016 Aug; 43(8):954-7. PubMed ID: 26945563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosis.
    Yanaba K; Asano Y; Noda S; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Tada Y; Sugaya M; Kadono T; Sato S
    Arch Dermatol Res; 2013 Jan; 305(1):17-23. PubMed ID: 23053221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
    Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
    Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis.
    van Bon L; Popa C; Huijbens R; Vonk M; York M; Simms R; Hesselstrand R; Wuttge DM; Lafyatis R; Radstake TR
    Ann Rheum Dis; 2010 Aug; 69(8):1539-47. PubMed ID: 20498209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database.
    Carreira PE; Carmona L; Joven BE; Loza E; Andreu JL; Riemekasten G; Vettori S; Balbir-Gurman A; Airò P; Walker UA; Damjanov N; Matucci-Cerinic M; Ananieva LP; Rednic S; Czirják L; Distler O; Farge D; Hesselstrand R; Corrado A; Caramaschi P; Tikly M; Allanore Y;
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):68-75. PubMed ID: 30277860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B).
    Servettaz A; Tamby MC; Guilpain P; Reinbolt J; Garcia de la Penã-Lefebvre P; Allanore Y; Kahan A; Meyer O; Guillevin L; Mouthon L
    Clin Immunol; 2006 Aug; 120(2):212-9. PubMed ID: 16580263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.
    Grassegger A; Pohla-Gubo G; Frauscher M; Hintner H
    Wien Med Wochenschr; 2008; 158(1-2):19-28. PubMed ID: 18286246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scleroderma and liver disease: a case of an association with primary sclerosing cholangitis.
    Zampetti A; Rinninella E; Manna R; Franceschi F
    Scand J Rheumatol; 2016 Jul; 45(4):334-5. PubMed ID: 26690847
    [No Abstract]   [Full Text] [Related]  

  • 19. Pilot study to determine whether transient receptor potential melastatin type 8 (TRPM8) antibodies are detected in scleroderma.
    Shah AA; Montagne J; Oh SY; Wigley FM; Casciola-Rosen L
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S123-6. PubMed ID: 26242276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-collagen type v: a marker of early systemic sclerosis?
    Ugolini-Lopes MR; Mantovani E; Bonoldi VLN; de Medeiros Ribeiro AC; Bonfá E; Yoshinari N; Andrade D
    Adv Rheumatol; 2019 May; 59(1):19. PubMed ID: 31088556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.